Savolitinib vs Telisotuzumab Vedotin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: MET · full Non-Small Cell Lung Cancer pipeline

Savolitinib · Orpathys

Marketed by AstraZeneca and partners

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT05015608 · Phase 3 · completed

The trial randomized 216 participants to savolitinib plus osimertinib or active chemotherapy, but treatment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT04322890 (registry estimate)

Reported efficacy

Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized): SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib. (met)

Result source: NCT05261399

Telisotuzumab Vedotin

Marketed by AbbVie

Approved in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2027 · NCT07323641 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSavolitinibTelisotuzumab Vedotin
PFS, median8.2 vs 4.5avs chemotherapyNCT05015608—Trial running · NCT04928846
OS, median—Not posted · NCT04923945—Trial running · NCT04928846
ORR62.1%abNCT04923945
1 other result
—Trial running · NCT04928846
Duration of response, median—Not posted · NCT04923945—Trial running · NCT04928846

PFS, median

Savolitinib
8.2 vs 4.5avs chemotherapyNCT05015608
Telisotuzumab Vedotin
—Trial running · NCT04928846

OS, median

Savolitinib
—Not posted · NCT04923945
Telisotuzumab Vedotin
—Trial running · NCT04928846

ORR

Savolitinib
62.1%abNCT04923945
1 other result
Telisotuzumab Vedotin
—Trial running · NCT04928846

Duration of response, median

Savolitinib
—Not posted · NCT04923945
Telisotuzumab Vedotin
—Trial running · NCT04928846
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Telisotuzumab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Savolitinib

PFS 8.2 vs 4.5 chemotherapy months
time to event · months
NCT05015608 · Phase 3 · sponsor-reported, not registry data
ORR 62.1%
responder rate · % of participants
No placebo or comparator arm
NCT04923945 · Phase 3 · sponsor-reported, not registry data
show 1 more result
39.2%
NCT04923945 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Savolitinib's landscape · Telisotuzumab Vedotin's landscape